ArticleDiscover oncology2026
Deciphering the contribution of 5'-tiRNA- Lys-CTT as an emerging early diagnostic biomarker for hepatocellular carcinoma.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) remains a leading cause of cancer mortality worldwide, with early detection critical for improving survival rates. Late-stage diagnosis contributes to dismal prognosis. Current surveillance relies on ultrasonography and serum alpha-fetoprotein (AFP), yet AFP exhibits limited sensitivity and specificity for early HCC. Emerging non-coding RNAs, particularly tRNA-derived small RNAs (tsRNAs), offer stable, detectable alternatives for liquid biopsy. Among these, 5′-tiRNA-Lys-CTT, a 5′-tRNA half derived from tRNA-Lys-CTT, has shown promise. This commentary explores the potential of 5′-tiRNA-Lys-CTT, a tRNA-derived small RNA (tsRNA), as an emerging biomarker for early HCC detection. It integrates biology, diagnostic performance along with recent advancements in tsRNA research for Hepatocellular carcinoma (HCC), and discusses potential clinical applications for enhanced early detection and personalized therapy. Ultimately, 5′-tiRNA-Lys-CTT represents a promising avenue for liquid biopsy-based screening, potentially revolutionizing HCC management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.